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Abstract  Amyotrophic  lateral  sclerosis  (ALS)  is  a  degenerative  neurological  disorder  that
affects motor  neurons.  Involvement  of  respiratory  muscles  causes  the  failure  of  the  ventila-
tor pump  with  more  or  less  signiﬁcant  bulbar  troubles.  ALS  course  is  highly  variable  but,  in
most cases,  this  disease  entails  a  very  signiﬁcant  burden  for  patients  and  caregivers,  especially
in the  end-of-life  period.
In order  to  analyze  the  characteristics  of  ALS  patients  who  die  at  home  (DH)  and  in  hospi-
tal (DHosp)  and  to  study  the  variability  of  clinical  practice,  a  retrospective  medical  records
analysis  was  performed  (n  =  77  from  ﬁve  hospitals).  Variables:  time  elapsed  since  the  onset  of
symptoms  and  the  beginning  of  ventilation,  characteristics  of  ventilation  (device,  mask  and
hours/day),  and  support  devices  and  procedures.
Results:  In  all,  14%  of  patients  were  ventilated  by  tracheotomy.  From  the  analysis,  57%  of
patients  were  of  DH.  Mean  time  since  the  onset  of  symptoms  was  35.93  ±  25.89  months,  signiﬁ-
cantly shorter  in  patients  who  DHosp  (29.28  ±  19.69  months)  than  DH  (41.12  ±  29.04)  (p  =  0.044). with  facial  ventilation  is  higher  in  DHosp  (11.4%  vs  39.4%,  p  <  0.005).The percentage  of  patients
DH or  not  is  related  to  a  set  of  elements  in  which  health  resources,  physician  atti-
tudes and  support  resources  in  the  community  play  a  role  in  the  decision-making  process.
There is  great  variability  between  countries  and  between  hospitals  in  the  same  country.
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Given  the  variability  of  circumstances  in  each  territory,  the  place  of  death  in  ALS  might  not
be the  most  important  element;  more  important  are  the  conditions  under  which  the  process
unfolds.
© 2013  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Local  do  óbito  em  doentes  com  esclerose  lateral  amiotróﬁca
Resumo  A  esclerose  lateral  amiotróﬁca  (ELA)  é  uma  perturbac¸ão  neurológica  degenerativa
que afeta  os  neurónios  motores.  O  envolvimento  dos  músculos  respiratórios  causa  a  falha  da
bomba ventilatória,  com  problemas  bulbares  mais  ou  menos  signiﬁcativos.  A  evoluc¸ão  da  ELA  é
bastante variável,  mas,  na  maioria  dos  casos,  esta  doenc¸a  implica  um  peso  muito  signiﬁcativo
para doentes  e  prestadores  de  cuidados,  em  particular  no  período  terminal.
Para analisar  as  características  dos  doentes  com  ELA  que  morrem  em  casa  (DH)  e  no  hospital
(DHosp), para  além  da  avaliac¸ão  da  variabilidade  das  práticas  clínicas,  foi  realizada  uma  análise
retrospetiva  dos  registos  médicos  (n=77  de  5  hospitais).  Variáveis:  tempo  decorrido  desde  o
aparecimento  dos  sintomas  e  o  início  da  ventilac¸ão,  características  da  ventilac¸ão  (dispositivo,
máscara e  horas/dia)  e  dispositivos  e  procedimentos  de  apoio.
Resultados:  Catorze  por  cento  dos  doentes  foram  tratados  por  traqueotomia.  Cinquenta  e  sete
por cento  dos  doentes  morreu  em  casa  (DH).  O  tempo  médio  desde  o  aparecimento  dos  sintomas
foi de  35,93  ±  25,89  meses,  signiﬁcativamente  inferior  em  doentes  que  morrem  no  hospital
(DHosp) (29,28  ±  19,69  meses)  comparativamente  com  os  que  morrem  em  casa  (DH)  (41,12
± 29,04)  (p=0,044).  A  percentagem  de  doentes  com  ventilac¸ão  facial  foi  superior  nos  DHosp
(11,4% vs  39.4%,  p<0,005).
DH  ou  não,  está  relacionado  a  um  conjunto  de  factores  em  que  os  recursos  de  saúde,  as
atitudes dos  médicos  e  o  apoio  na  comunicac¸ão  desempenham  um  papel  importante  na  tomada
de decisão.  Existe  uma  grande  variabilidade  entre  países  e  entre  hospitais  no  mesmo  país.
Dada a  variabilidade  de  circunstâncias  em  cada  território,  o  local  do  óbito  na  ELA  poderá  não
ser o  elemento  mais  importante,  sendo  provavelmente  mais  relevantes  as  condic¸ões  em  que  o
processo se  desenrola.
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Introduction
Amyotrophic  lateral  sclerosis  (ALS)  is  a  degenerative  neu-
rological  disorder  that  affects  motor  neurons,  causing
progressive  and  irregular  loss  of  muscle  strength.  ALS
progressively  affects  ventilatory  pump  with  more  or  less  sig-
niﬁcant  bulbar  involvement.  The  course  of  the  disease  is
highly  variable,  and  although  lung  function  has  prognostic
value,1 it  has  no  predictive  value  since  the  loss  of  respiratory
muscle  function  can  occur  abruptly.
This  disease  entails  a  very  signiﬁcant  burden  for
caregivers,2 both  from  the  perspective  of  care  and  from  the
economic  and  emotional  aspects.  In  recent  years  there  has
been  a  change  of  attitude  toward  tackling  the  disease.  Ini-
tially  the  clinicians’  position  was  more  pessimistic  about  the
treatment,  citing  the  poor  short-term  prognosis.  However,
the  introduction  of  noninvasive  ventilation,  percutaneous
gastrostomy  and  mechanical  aids  for  cough  augmentation3
improved  the  quality  of  life  of  patients  and,  possibly,  even
their  survival.  One  of  the  challenges  facing  most  health  sys-
tems  is  to  respond  to  the  needs  of  these  complex  patients
in  the  ﬁnal  stages  of  life.
Previous  studies  have  shown  the  main  issues  for  patients
and  caregivers  for  coping  with  the  disease,  especially  dur-
ing  the  end-of-life  period:  overall,  ALS  patients  were  aware
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f  their  prognosis  and  disease  severity,  having  been  kept
ell  informed  by  their  doctors.  Caregivers  reported  control
f  symptoms  in  their  relatives  but  the  relief  of  the  respi-
atory  symptoms  was  not  easily  achieved  despite  the  use
f  drugs  and  sedatives.  Family  burden  and  hospitalization
ccess  were  high.  Deaths  were  equally  distributed  between
ome  and  hospital,  and  NIV  use  and  diagnosis  inﬂuenced
amilial  reporting.4
The  aim  of  this  study  was  to  analyze  the  characteristics
f  ALS  patients  who  die  at  home  and  in  hospital  and  to  study
he  degree  of  variability  of  clinical  practice.  Moreover,  it
imed  at  identifying  the  elements  that  can  improve  care
n  the  ﬁnal  stages  of  life  in  order  to  design  care  projects
apable  of  responding  to  patients’  real  needs.
ethods
his  retrospective  study  was  conducted  in  ﬁve  hospitals
rom  the  north  of  Italy  and  Catalonia  (Spain)  by  analyz-
ng  medical  records  of  ALS  patients  treated  at  the  hospital
nd  who  died  of  the  disease.  Four  hospitals  were  public
ospitals  with  beds  dedicated  to  acute  care  and  ﬁfth  was
 private  center  (Fondazione  S.  Maugeri  IRCCS)  involved
n  rehabilitation/long-term  needs  and  research  for  chronic
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Table  1  Hospital  distribution.
Total,  n  (%)* Home,  n  (%)  *  Hospital,  n  (%)  *  %  pts  dying  at
home  per  hospital
Hospital
Fondazione  S.  Maugeri  IRCCS,  Lumezzane  24  (31.2%)  9  (20.5%)  15  (45.5%)  37.5
Ospedale Civile,  Padova  16  (20.8%)  13  (29.4%)  3  (9.1%)  81
Azienda Ospedaliero-Universitaria  Pisana  12  (15.6%)  9  (20.5%)  3  (9.1%)  75
Hospital Universitari  de  Bellvitge  16  (20.8%)  9  (20.5%)  7  (21.2%)  56
Hospital del  Mar  9  (11.7%)  4  (9.1%)  5  (15.2%)  44
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TP value: 0.045.
* % related to the total number of patients.
iseases,  but  in  all  cases  patients  do  not  have  to  pay  any
oney  at  the  time  of  care.
In  2010  all  cases  of  patients  diagnosed  with  ALS  in
very  hospital  who  had  died  in  the  previous  twelve  months
hether  at  the  hospital  or  in  a  health  care  facility  or  at  home
ere  analyzed.
The  variables  considered  in  each  patient  were  age  (years)
nd  gender  (male/female),  time  elapsed  since  the  onset  of
ymptoms  (months)  (TEOS),  time  elapsed  since  the  begin-
ing  of  ventilation  (months)  (TEBV),  type  of  ventilation
rescription  (elective/acute),  characteristics  of  the  venti-
ation  in  the  last  week  of  life  (pressure,  volumetric),  type
f  mask  used  (nasal/facial),  number  of  hours  of  ventilation
n  the  last  week  (measured  according  to  the  data  of  the
edical  record),  management  of  secretions  (use  of  cough
ssist,  bag  or  manual  in  the  medical  record),  presence  of
ercutaneous  endoscopic  gastrostomy  (PEG),  and  drug  con-
umption  (morphine,  benzodiazepine,  other).  The  deﬁnition
f  the  type  of  ALS  (spinal/bulbar)  was  deﬁned  according  to
he  clinical  information,  with  or  without  objective  data.
tatistical  analysis
atient  population  was  classiﬁed  into  two  subgroups  accord-
ng  the  place  of  death:  home  or  hospital.  Statistical  analysis
as  performed  using  SPSS  13.2  software  (SPSS  Inc.,  Chicago,
L,  USA).  A  descriptive  analysis  of  variables  derived  by
edical  record  was  performed  (expressed  as  %).  Binary
i
o
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Table  2  Patient  characteristics  and  onset  of  the  disease.
Total,  n  (%)  
Gender
Male  43  (55.8%)  
Female 34  (44.2%)  
ALS onset
Bulbar  46  (59.7%)  
Spinal 31  (40.3%)  
Initiation of  ventilation
Elective  57  (78%)  
Acute phase  16  (22%)  
Gender: p value = 0.186.
ALS onset: p value = 0.357.
Initiation of ventilation: p value = 0.95.ogistic  regression  was  performed  using  ‘‘place  of  death’’
s  dependent  variable.  A  two-sided  p-value  <  0.05  was  con-
idered  to  be  statistically  signiﬁcant.
esults
he  medical  record  of  77  patients  (women:  44.2%,  mean
ge:  66.3  ±  11.9  yrs)  was  analyzed.  There  were  no  differ-
nces  regarding  age  related  to  the  place  of  death.
ospital  distribution
n  all,  57%  of  patients  died  at  home.  The  probability  of  dying
t  home  is  signiﬁcantly  related  to  the  hospital  where  the
atient  is  cared  for.  The  percentage  of  patients  who  died
n  hospital  ranged  from  18.7%  to  62.5%  (p  =  0.045).  Table  1
hows  the  distribution  of  the  ﬁve  hospitals  of  the  patients
ccording  to  the  place  of  death.
ariables  related  to  the  patient  and  the  onset  of
he disease
here  are  no  differences  regarding  age,  gender,  character-
stics  of  the  onset  of  the  disease  (bulbar  or  spinal)  or  type
f  ventilation  prescription  (elective  or  acute)  (Table  2).
Mean  time  elapsed  since  the  onset  of  symptoms  (months)
TEOS)  was  35.93  ±  25.89  months,  signiﬁcantly  shorter  in
Home,  n  (%)  Hospital,  n (%)
27  (61.4%)  16  (48.5%)
17  (38.6%)  17  (51.5%)
25  (56.8%)  21  (63.6%)
19  (43.2%)  12  (36.4%)
33  (78.6%)  24  (77.4%)
9  (21.4%)  7  (22.6%)
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Table  3  Variables  related  to  ventilation.
Total,  n  (%)  Home,  n  (%)  Hospital,  n  (%)
Characteristics  of  the  ventilation  in  the  last  week
Nasal  ventilation  37  (48.1%)  24  (54.5%)  13  (39.4%)
Tracheal ventilation  11  (14.3%)  9  (20.5%)  2  (6.1%)
Facial ventilation  18  (23.4%)  5  (11.4%)  13  (39.4%)
Nasal +  oral  ventilation  6  (7.8%)  4  (9.1%)  2  (6.1%)
Other 5  (6.5%)  2  (4.5%)  3  (9.1%)
Number of  hours  (in  the  last  week)
Only  during  the  night  8  (10.4%)  6  (13.6%)  2  (6.1%)
8--12 h 10  (13%) 6  (13.6%)  4  (12.1%)
12--16 h 10  (13%) 8  (18.2%) 2  (6.1%)
16--18 h 14  (18.2%) 5  (11.4%) 9  (27.3%)
18--23 h  7  (9.1%)  4  (9.1%)  3  (9.1%)
24 h/day  21  (27.3%)  11  (25.0%)  10  (30.3%)
Characteristics  of  ventilator
VOLUME  18  (25.7%)  14  (35.0%)  4  (13.3%)
PRESSURE 52  (74.3%)  26  (65.0%)  26  (86.7%)
Ventilation in the last week p value = 0.029.
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Characteristics of ventilator p value = 0.036.
patients  who  died  in  hospital  (29.28  ±  19.69  months)  than
at  home  (41.12  ±  29.04)  (p  =  0.044).
Variables  related  to  ventilation  during  the  last
week
The  variables  related  to  ventilation  during  last  week  are
shown  in  Table  3.
The  place  of  death  is  signiﬁcantly  related  to  the  char-
acteristics  of  ventilation  during  the  last  week,  speciﬁcally
related  to  the  airway  interface  (p  =  0.029):  %  of  patients  with
facial  ventilation  is  higher  in  the  hospital  group  (11.4%  vs
39.4%,  p  <  0.005),  and  also  to  the  type  of  ventilator:  the  per-
centage  of  patients  using  volume  ventilator  is  signiﬁcantly
higher  among  those  who  die  at  home  (p  <  0.036).
The  percentage  of  patients  who  are  ventilated  by  tra-
cheotomy  in  the  study  group  is  14%  (17%  in  patients  with
bulbar  involvement  and  9%  in  patients  without  bulbar
involvement).  There  are  no  signiﬁcant  differences  regarding
the  invasive  access  to  the  airway  (namely  tracheo  or  not)
related  to  the  place  of  death.
Variables  related  to  care  during  the  last  week
There  were  no  signiﬁcant  differences  in  drug  consumption
(amitriptyline,  baclofen,  benzodiazepines,  lithium  carbon-
ate,  morphine  or  riluzole)  during  the  last  week  of  life,
except  in  the  case  of  omeprazole,  the  use  of  which  was
signiﬁcantly  higher  in  hospital  (p  <  0.044).
There  were  no  signiﬁcant  differences  in  access  to  devices
or  methods  for  managing  secretions  among  patients  who  die
in  hospital  or  at  home  or  in  the  use  of  PEG.
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n  our  retrospective  study  the  place  of  death  is  signiﬁcantly
elated  to  the  hospital,  the  time  elapsed  since  the  onset  of
ymptoms  and  the  type  of  airway  access  in  the  last  week.
There  are  limitations  to  the  interpretation  of  our  ﬁnd-
ngs,  especially  in  relation  to  the  sample  size  and  the  number
f  hospitals  studied.  However,  these  preliminary  data  sug-
est  that  the  organization  of  health  care  and  some  aspects
f  the  disease  may  play  a  role.
We  found  signiﬁcant  differences  in  the  percentage  of
atients  who  die  at  home  according  to  the  hospital.  The  pos-
ibility  of  dying  at  home  or  not  is  related  to  a set  of  elements
n  which  health  resources,  physician  attitudes  and  support
esources  in  the  community  play  a role  in  the  decision-
aking  process.
In France  only  36%  of  patients  died  outside  medical  facil-
ties  (mainly  at  home).5 Most  French  patients  die  in  acute
ospitals  and  only  12%  out  of  the  total  die  in  hospices  or
ong-term  care  facilities.
The  variability  within  the  same  country  is  very  high,  as
e  can  see  in  the  results  of  the  three  Italian  hospitals.  In  one
egion  of  Italy  over  85%  of  patients  die  at  home.6 However,
hese  data  should  be  interpreted  with  caution,  since  in  many
ases  they  refer  to  hospital  records  and  not  to  population
nalysis.  In  order  to  understand  the  patients’  preferences  it
ight  be  interesting  to  analyze  the  role  of  reference  cen-
ers.
It  seems  logical  to  think  that  a  reference  center  improves
utcomes  because  it  focuses  on  the  knowledge  and  skills
eeded  to  manage  complex  patients  as  in  the  case  of  ALS.
owever,  the  beneﬁts  are  more  related  to  the  intensity  of
nterventions  than  to  the  concentration  of  patients.  Zoc-
olella  et  al.7 showed  that  multidisciplinary  clinics  did  not
mprove  survival.  In  this  study  the  rate  of  interventions
n  both  the  groups  (multidisciplinary  clinic  and  general
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eurology  clinic)  was  very  low:  only  2.5%  of  patients  used
IV  in  both  groups  and  6%  of  patients  in  multidisciplinary
linic  used  PEG.
Another  bias  in  the  analysis  of  the  beneﬁts  of  refer-
nce  centers  is  in  recruitment.  Some  evidence  suggest  that
roactive  and  aggressive  therapy  improves  survival.8 Hutchi-
on  et  al.9 suggested  that  the  ALS  clinic  treated  a  group
f  ﬁtter  ALS  patients  and  the  general  neurologists  saw  all
atients  (especially  patients  living  further  from  ALS  clinic,
ore  disabled  or  older).  Chiò  et  al.10 conﬁrm  this  approach.
atients  treated  in  specialized  clinics  are  four  years  younger
han  those  treated  at  non-specialized  neurology  clinics,  they
eceive  more  aggressive  treatments  (PEG  and  NIV),
hey  have  fewer  hospital  admissions,  and  most  of  the  hospi-
al  admissions  are  planned.
There  are  doubts  about  the  beneﬁts  of  a  living  will11
o  help  physicians  make  clinical  decisions  at  the  end  of
ife,  mainly  with  respect  to  the  decision  to  perform  a tra-
heotomy  or  for  the  patient  to  die  at  home  or  in  hospital.
he  most  important  factor  is  the  doctor’s  communication
kills.
A  diverse  but  interrelated  set  of  factors  inﬂuence  patient
hoices  and  attitudes  about  living  and  dying  with  ALS.
here  are  speciﬁc  circumstances  that  change  attitudes
bout  death  and  the  place  of  death.  In  the  Netherlands,
n  2000--2005  16.8%  of  ALS  patients  chose  the  option  of
uthanasia  or  physician-assisted  suicide  (PAS),  and  14.8%
ied  during  continuous  deep  sedation  (CDS).12 This  attitude
s  not  uniform  across  countries,  and  ethical  issues  emerge
s  a  main  element  of  care  plan  throughout  the  course  of  the
isease.13 The  increase  in  interventions  in  the  end-of-life
eriod  is  likely  to  increase  admissions  to  hospitals  or  health
are  facilities.
The  time  elapsed  since  the  onset  of  symptoms  is  an
mportant  prognostic  factor.  As  Kaufmann  et  al.14 showed,
ymptom  duration  at  baseline  visit  was  a  signiﬁcant  predic-
or  of  survival:  shorter  duration  means  higher  mortality.
The  patients’  preferences  regarding  treatment  choices
hange  over  time.  Patients  who  found  the  interventions
cceptable  (PEG,  NIV  or  tracheo)  for  life-extending  were
ore  likely  to  be  recently  diagnosed.15 One  possible  expla-
ation  for  the  fact  that  patients  who  die  in  hospital  had  a
horter  course  of  the  disease  could  be  a  positive  attitude
oward  more  aggressive  treatments.  In  our  study,  the  dis-
ase  course  is  a  year  longer  in  patients  who  die  at  home.
nother  possible  explanation  could  be  that  adaptation  to  a
isease  as  serious  as  ALS  takes  time.
Over  60%  of  patients  using  facial  mask  in  the  last  week
ie  in  hospital.  A  total  face  mask  is  a  possible  option  for
atients  in  acute  respiratory  failure  with  leaks  or  nose  bridge
kin  problems.16 There  are  no  objective  reasons  for  the
ncreased  use  of  face  mask  ventilation  in  patients  who  die
n  the  hospital.  But  it  seems  clear  that  it  is  more  difﬁcult
o  care  for  patients  with  a  facial  mask  compared  with  those
ho  only  need  a  nasal  mask.
There  is  no  speciﬁc  reason  for  the  greater  chance  of  dying
n  hospital  for  the  patients  who  use  a  face  mask.  Perhaps
hese  patients  have  worsened  and  do  not  want  tracheotomy,
o  the  facial  mask  is  an  alternative,  or  perhaps  the  use  of
 facial  mask  is  an  overload  for  the  caregiver  because  with
acial  mask  ﬂuid  intake  and  communication  is  much  more
ifﬁcult.
C
TJ.  Escarrabill  et  al.
Tracheotomy  does  not  prevent  discharging  severe
LS  patients  home.  Lo  Coco  et  al.  showed  that  92%  of  ALS
atients  with  tracheotomy  could  go  back  home,  with  a
edian  survival  time  of  37  months,17 and  Vianello  et  al.18
howed  that  87%  of  patients  die  at  home.  In  our  survey,  80%
f  patients  with  a tracheotomy  die  at  home,  a  similar  per-
entage  to  that  described  by  Lo  Coco  and  Vianello.  Although
t  may  seem  paradoxical,  patients  with  tracheotomy  might
epresent  less  of  a  burden  for  the  caregiver  in  ensuring
ffective  ventilation.  Suctioning  is  also  easier  through  the
racheostomy.
In  our  study  no  differences  were  observed  regarding  the
lace  of  death  in  relation  to  the  presence  or  absence  of
ulbar  involvement.  Further  studies  are  needed  to  exam-
ne  the  relationship  between  bulbar  involvement  and  place
f  death  in  patients  with  ALS.  The  percentage  of  patients
ho  are  ventilated  by  tracheotomy  in  the  study  group  is
4%.  This  percentage  is  slightly  higher  in  the  group  with
ulbar  involvement  (17%).  Perhaps  this  small  difference  in
avor  of  the  tracheotomy  minimizes  the  impact  of  bulbar
nvolvement  as  a determinant  of  place  of  death.
The  accessibility  of  drugs  and  devices  for  secretion  man-
gement  is  the  same  for  both  the  groups  of  patients.  This
act  emphasizes  that  death  at  home  does  not  mean  under-
reatment.
The  analysis  of  the  place  of  death  in  ALS  should  not
e  restricted  to  discussion  of  the  hospital  or  at  home.
s  Servera  et  al.19 pointed  out,  the  care  of  patients  with
LS  should  be  evaluated  comprehensively.  The  therapy
‘package’’  should  include  devices  or  techniques  for  respi-
atory  support  or  nutrition,  but  the  therapy  ‘‘package’’
ust  also  include  the  organization  of  care  in  the  community
nd  easy  communication  with  expert  teams.  Telemedicine20
lays  a crucial  role  in  an  integrated  care  model.  Hospice  or
ealth  care  facilities  could  be  useful  for  patients  dependent
n  a  ventilator  who  lack  family  support.21
It  is  very  difﬁcult  to  establish  the  criteria  for  the  best
lace  to  meet  the  needs  of  the  end-of-life  stages  in  patients
ith  ALS.  It  is  necessary  to  establish  care  plans  to  meet  the
eeds  of  each  patient,  according  to  the  resources  that  are
ocally  available.
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